3 results
primaryTo assess the safety and tolerability of multiple, once-daily oral doses of RDN-929 over 28 days in healthy older adult subjects and early symptomatic AD subjects.secondaryTo assess the plasma and CSF pharmacokinetics (PK) of RDN-929 in…
The current trial aims to demonstrate that sugammadex is generally safe and effective for reversing both moderate and deep block after rocuronium or vecuronium induced NMB in term neonates and young children.
The primary objective of this study is to assess the effects of CPPF, executed by Haermonics Flush, in comparison with standard care on clinically relevant endpoints, like re-explorations, in a population of cardiac surgery patients that have an…